The PTCT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PTCT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PTCT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PTCT Detailed Price Forecast - CNN Money||View PTCT Detailed Summary - Google Finance|
|View PTCT Detailed Summary - Yahoo! Finance||View PTCT Stock Research & Analysis - Zacks.com|
|View PTCT Trends & Analysis - Trade-Ideas||View PTCT Major Holders - Barrons|
|View PTCT Call Transcripts - NASDAQ||View PTCT Breaking News & Analysis - Seeking Alpha|
|View PTCT Annual Report - CompanySpotlight.com||View PTCT OTC Short Report - OTCShortReport.com|
|View PTCT Fundamentals - TradeKing||View PTCT SEC Filings - Bar Chart|
|View Historical Prices for PTCT - The WSJ||View Performance/Total Return for PTCT - Morningstar|
|View the Analyst Estimates for PTCT - MarketWatch||View the Earnings History for PTCT - CNBC|
|View the PTCT Earnings - StockMarketWatch||View PTCT Buy or Sell Recommendations - MacroAxis|
|View the PTCT Bullish Patterns - American Bulls||View PTCT Short Pain Metrics - ShortPainBot.com|
|View PTCT Stock Mentions - StockTwits||View PTCT Stock Mentions - PennyStockTweets|
|View PTCT Stock Mentions - Twitter||View PTCT Investment Forum News - Investor Hub|
|View PTCT Stock Mentions - Yahoo! Message Board||View PTCT Stock Mentions - Seeking Alpha|
|View Insider Transactions for PTCT - SECform4.com||View Insider Transactions for PTCT - Insider Cow|
|View PTCT Major Holdings Summary - CNBC||View Insider Disclosure for PTCT - OTC Markets|
|View Insider Transactions for PTCT - Yahoo! Finance||View Institutional Holdings for PTCT - NASDAQ|
|View PTCT Stock Insight & Charts - FinViz.com||View PTCT Investment Charts - StockCharts.com|
|View PTCT Stock Overview & Charts - BarChart||View PTCT User Generated Charts - Trading View|
PTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Posted on Thursday April 12, 2018
SOUTH PLAINFIELD, N.J. , April 12, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the underwriters of its previously announced public offering of 4,000,000 shares of its ...
PTC Therapeutics Announces R&D Day to Review Multiple Orphan Disorder Programs
Posted on Monday April 09, 2018
SOUTH PLAINFIELD, N.J. , April 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it will hold its R&D Day on Tuesday, April 17, 2018 from 12:00 p.m. to 5:00 p.m. ET in New York ...
PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease
Posted on Wednesday April 04, 2018
SOUTH PLAINFIELD, N.J., April 4, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) and the CHDI Foundation, Inc. (CHDI) today announced a research collaboration to advance PTC's Huntington's disease program. The program is optimizing small-molecule compounds—identified using PTC's splicing technology platform—that decrease the production of huntingtin protein. The current compounds have been shown to be orally bioavailable in animals, blood-brain barrier penetrant, and effective in decreasing the amount of huntingtin protein in a mouse model that has the expanded human huntingtin transgene.
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
Posted on Wednesday March 28, 2018
In addition, PTC has granted the underwriters an option for a period of 30 days to purchase up to an additional 600,000 shares of common stock at the public offering price, less the underwriting discount. Credit Suisse and Citigroup are acting as lead book-running managers for the offering. RBC Capital Markets is also acting as a book-running manager.